Please assess the completion status of the following clinical trial:

Trial Title: Immunologic Response to FluMist vs. Flucelvax

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* aged 4-21 years;~* has prior vaccination history available (which can be determined based either on medical record review or through state registry review);~* plans to receive the current seasonal influenza vaccination at one of the recruiting sites~Exclusion Criteria:~* unable or unwilling to completed required study activities, including informed consent, randomization to vaccine, and bloodwork;~* has already received influenza vaccine for the current season;~* has a known immunocompromising condition or is on an immunosuppressing medication (e.g., high dose steroids \>10 days);~* is known to be pregnant;~* has a history of severe allergy to eggs or to influenza vaccine or any of its components

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 21 Years
- Healthy Volunteers: t

Study Arms:
- FluMist live attenuated influenza vaccine (Type: ACTIVE_COMPARATOR): Participants receiving live attenuated FluMist influenza vaccine will receive 0.2 mL given intranasally
- Flucelvax inactivated influenza vaccine (Type: ACTIVE_COMPARATOR): Participants receiving inactivated Flucelvax influenza vaccine will receive 0.5 mL given intramuscularly

Based on this trial design, predict the completion outcome and termination type (if applicable).